VYNE announces $88M PIPE funding and positive clinical data for VYN201 and VYN202

VYNE Therapeutics Inc.

Raised $88M gross from PIPE led by Access Biotechnology, with participation from healthcare investors.
Phase 1b VYN201 vitiligo trial: 1.0% cohort 30.3% mean F-VASI reduction (p=0.0137), 2.0% cohort 39.0% (p=0.0077) vs 0.5%.
VYN202 preclinical: 95% PASI reduction in psoriasis model; 71% reduction in rheumatoid arthritis signs/symptoms.
Preliminary cash $15.5M as of Sep 30, 2023; with PIPE proceeds pro forma $103.7M.
Next steps: Phase 2b VYN201 in vitiligo in 1H2024; Phase 1a VYN202 trial expected Q1 2024.

item 1.01 item 1.02 item 2.02 item 3.02 item 5.08 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VYNE Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $88.2 million (effective 2023-10-27).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and other accredited investors
Value: $88.2 million
Effective: 2023-10-27

Exact text from the filing

On October 27, 2023, VYNE Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VYNE Therapeutics Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2023-10-30).

Action: termination
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, the Company delivered a notice of termination to Lincoln Park terminating the Purchase Agreement effective as of one business day following delivery of notice.

View on SEC.gov

Browse all material agreements →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-112359

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.